Development of Monoclonal Antibodies in China: Overview and Prospects

Monoclonal antibodies (mAbs) have become increasingly important as human therapeutic agents. Yet, current research concentrates on technology itself and pays attention to developed countries. This paper aims to provide a comprehensive review of mAbs development in China through systematic analysis o...

Full description

Saved in:
Bibliographic Details
Published inBioMed research international Vol. 2015; no. 2015; pp. 1 - 10
Main Authors Wang, Yi-Tao, Hu, Hao, Gao, Zi-Chao, Wang, Liang, Lu, Jin-Jian, Zhang, Mao-Yu, Ung, Carolina Oi Lam
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 01.01.2015
John Wiley & Sons, Inc
Hindawi Limited
Subjects
Antibodies, Monoclonal - biosynthesis
Antigens
Biomedical research
China
Clinical trials
Clinical Trials as Topic
FDA approval
Humans
Industrialized nations
Medical research
Monoclonal antibodies
Pharmaceutical industry
Product development
Protein Engineering - methods
R&D
Research & development
Review
Science
China
United States > US
Online AccessGet full text

Cover

More Information
Summary:Monoclonal antibodies (mAbs) have become increasingly important as human therapeutic agents. Yet, current research concentrates on technology itself and pays attention to developed countries. This paper aims to provide a comprehensive review of mAbs development in China through systematic analysis of drug registry, patent applications, clinical trials, academic publication, and ongoing R&D projects. The trends in therapeutic areas and industrialization process are also highlighted. Development and research trends of mAbs are analyzed to provide a future perspective of mAbs as therapeutic agents in China.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Review-1
Academic Editor: Michael Hust
ISSN:2314-6133
2314-6141
DOI:10.1155/2015/168935